LECAP Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

LECAP Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,009	Closed	-$217K	–	291
2025 Q3	$217K	Sell	4,009 -6,793	-63%	-$388K	0.08%	263
2025 Q2	$594K	Buy	10,802 +980	+10%	+$57.7K	0.21%	177
2025 Q1	$694K	Buy	9,822 +1,330	+16%	+$89.5K	0.16%	210
2024 Q4	$558K	Sell	8,492 -5,863	-41%	-$393K	0.15%	210
2024 Q3	$1.01M	Buy	+14,355	New	+$1.2M	0.22%	170
2024 Q2	–	Sell	-11,000	Closed	-$961K	–	323
2024 Q1	$961K	Buy	11,000 +4,658	+73%	+$417K	0.2%	189
2023 Q4	$611K	Buy	+6,342	New	+$561K	0.22%	170

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LECAP Asset Management's BMRN Position: Q4 2025 in Review

LECAP Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 4,009 shares — an estimated $217K sold.

LECAP Asset Management first reported a position in BMRN in Q4 2023 and held it in 7 quarters. The position peaked at $1.01M in Q3 2024. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

LECAP Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
LECAP Asset Management sold 4,009 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $217K.
LECAP Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 7 quarters.
LECAP Asset Management's BioMarin Pharmaceuticals position peaked at $1.01M in Q3 2024.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on LECAP Asset Management's 13F filing for Q4 2025, filed 27 Jan 2026.